Interestingly, especially when considering global SHP-1 inhibition with agents such as SSG or TPI-1, SHP-1 expression is altered in a range of malignancies; up-regulated in breast and ovarian cancers [63,64], and gene-silenced in lymphomas, leukaemias and colorectal cancers [65–67]. This evidence concerns the gene NR0B2 and leukemia.